Mevalonate pathway antagonist suppresses formation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models

Clinical Cancer Research

Volumn 21, Issue 20, 2015, Pages 4652-4662

  Kobayashi, Yusuke ^a,b,c   Kashima, Hiroyasu ^a,b   Wu, Ren Chin ^a,b,d   Jung, Jin Gyoung ^a,b   Kuan, Jen Chun ^a,b   Gu, Jinghua ^e   Xuan, Jianhua ^e   Sokoll, Lori ^a,b   Visvanathan, Kala ^b,f   Shih, Ie Ming ^a,b   Wang, Tian Li ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c KEIO UNIVERSITY   (Japan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; PHOSPHOLIPASE C; RHO KINASE; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DNA REPLICATION; DRUG MECHANISM; DRUG POTENCY; FEMALE; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PRENYLATION; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE TUBE CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA IN SITU; DISEASE MODEL; DRUG EFFECTS; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA REPLICATION; FEMALE; HUMANS; LOVASTATIN; MEVALONIC ACID; MICE; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84945534822     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3368     Document Type: Article

References (43)

1. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 2008;371:303-14.
2. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35.
3. National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/factsheet/Risk/oral-contraceptives. [cited 2015 March 21].
4. Michelsen TM, Dorum A, Dahl AA. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol 2009;113:128-33.
5. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 2007;25: 2921-7.
6. Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med 2015;12:189-97.
7. Moldovan R, Keating S, Clancy T. The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome. Fam Cancer 2015;14:51-60.
8. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012;148:244-58.
9. Katz DH, Intwala SS, Stone NJ. Addressing statin adverse effects in the clinic: the 5 Ms. J Cardiovasc Pharmacol Ther 2014;19:533-42.
10. Li AJ, Elmore RG, Chen IY, Karlan BY. Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. Gyne-col Oncol 2010;116:78-81.
11. Bernstein AB, Makuc DM, Bilheimer LT. Health, United States, 2011: With special feature on socioeconomic status and health; 2012. Hyattsville MD: CDC/OSELS/NCHS/OD/Office of Information Services, Information Design and Publishing Staff.
12. Baandrup L, Dehlendorff C, Friis S, Olsen JH, Kjaer SK. Statin use and risk for ovarian cancer: a Danish nationwide case-control study. Br J Cancer 2015;112:157-61.
13. Liu Y, Qin A, Li T, Qin X, Li S. Effect of statin onriskof gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. Gynecol Oncol 2014;133:647-55.
14. Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 2008;111:102-5.
15. Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol 2013; 130:615-9.
16. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802.
17. Miyoshi I, Takahashi K, Kon Y, Okamura T, Mototani Y, Araki Y, et al. Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. Mol Reprod Dev 2002;63:168-76.
18. Sherman-Baust CA, Kuhn E, Valle BL, Shih Ie M, Kurman RJ, Wang TL, et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 2014;233:228-37.
19. Asakura K, Izumi Y, Yamamoto M, Yamauchi Y, Kawai K, Serizawa A, et al. The cytostatic effects of lovastatin on ACC-MESO-1 cells. J Surg Res 2011;170:e197-209.
20. Kuhn E, Kurman RJ, Soslow RA, Han G, Sehdev AS, Morin PJ, et al. The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol 2012;36: 1826-34.
21. Burg JS, Espenshade PJ. Regulation of HMG-CoA reductase in mammals and yeast. Prog Lipid Res 2011;50:403-10.
22. Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep 2011;25:41-7.
23. Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 2010;10:103.
24. Liu H, Liang SL, Kumar S, Weyman CM, Liu W, Zhou A. Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol 2009;63: 997-1005.
25. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012;24:602-8.
26. Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, et al. Real-time intravital imaging establishes tumor-associated macrophages as the extra-skeletal target of bisphosphonate action in cancer. Cancer Discov 2015;5:35-42.
27. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001;15: 1398-407.
28. Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 2008;8:9.
29. Huang EH, Johnson LA, Eaton K, Hynes MJ, Carpentino JE, Higgins PD. Atorvastatin induces apoptosis in vitro and slows growth of tumor xeno-grafts but not polyp formationinMIN mice. Dig Dis Sci 2010;55:3086-94.
30. Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosisincolon cancer cells. Int J Cancer 2008;122:2115-24.
31. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-transla-tional modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-55.
32. Park JB, Lee CS, Jang JH, Ghim J, Kim YJ, You S, et al. Phospholipase signalling networks in cancer. Nat Rev Cancer 2012;12:782-92.
33. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
34. Bailis JM, Forsburg SL. MCM proteins: DNA damage, mutagenesis and repair. Curr Opin Genet Dev 2004;14:17-21.
35. Bell SD, Botchan MR. The minichromosome maintenance replicative helicase. Cold Spring Harb Perspect Biol 2013;5:a012807.
36. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.
37. Caruso MG, Notarnicola M, Cavallini A, Di Leo A. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer. J Gastroenterol 2002;37:504-8.
38. Notarnicola M, Messa C, Pricci M, Guerra V, Altomare DF, Montemurro S, et al. Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res 2004;24:3837-42.
39. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A 2010;107:15051-6.
40. Maltese WA. 3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 1983;33:1294-9.
41. Butt S, Butt T, Jirstrom K, Hartman L, Amini RM, Zhou W, et al. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Ann Surg Oncol 2014;21:2911-9.
42. Bengtsson E, Nerjovaj P, Wangefjord S, Nodin B, Eberhard J, Uhlen M, et al. HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome. Diagn Pathol 2014;9:78.
43. Kuhn E, Kurman RJ, Shih IM. Ovarian cancer is animported disease: fact or fiction? Curr Obstet Gynecol Rep 2012;1:1-9.